SLC5A2 and familial primary hypomagnesemia: The findings from the included studies suggest that SGLT2 inhibitor therapy may lead to significant improvements in serum magnesium levels and correction of hypomagnesemia, even in patients with long-standing and treatment-resistant cases. Further exploration of the mechanisms underlying the magnesium-modulating effects of SGLT2 inhibitors may pave the way for novel therapeutic strategies and personalized approaches to maintaining magnesium homeostasis.